Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Daily Wrap: The Biggest Hedge Fund Moves of the Day

Page 1 of 2

OZ Management All Over The Nutanix IPO

Billionaire Daniel S. Och‘s OZ Capital Management initiated a position in Nutanix Inc. (NASDAQ:NTNX), as reported in a 13G filing yesterday. The fund has acquired 1 million Class A shares of the company, which amass 5.85% of Nutanix’s outstanding stock. Nutanix Inc. (NASDAQ:NTNX) is a software company that offers an enterprise cloud platform, which converges computing, virtualization and storage into one solution. The company went public on September 29 at $16 per share and has more than doubled in value since then, continuing the trend of IPOs shooting impressively out of the starting gate this year. Maxim Group initiated coverage of Nutanix Inc. (NASDAQ:NTNX) on September 30 with a ‘Buy’ rating and $40 price target, which shares nearly reached within their first trading session despite the extremely bullish call. There are no other known shareholders of Nutanix among the funds that we track as of this time.

Through extensive research that covered the portfolios of several hundred large investors between 1999 and 2012, we determined that following the small-cap stocks that large money managers are collectively bullish on, can generate monthly returns nearly 1.0 percentage points above the market (see the details here).

Och-Ziff Capital Management

D E Shaw Trims Exact Sciences Stake

A separate 13G filing showed that D E Shaw, founded by billionaire David E. Shaw, has slightly lowered its stake in Exact Sciences Corp (NASDAQ:EXAS), as it now holds 5.41 million common shares of the company, which account for 5% of its float. The current stake has been lowered from 5.44 million shares of Exact Sciences Corp (NASDAQ:EXAS) owned on August 15, which represented 5% of the company’s outstanding stock, as reported in the fund’s previous 13G filing on the company. Shares of the molecular diagnostics company, which has a focus on the early detection and prevention of various types of cancer, were held by 16 of the hedge funds in our database at the end of June, including Steve Cohen’s Point72 Asset Management, Charles Paquelet’s Skylands Capital, and Ken Griffin’s Citadel Investment Group.

Follow Exact Sciences Corp (NASDAQ:EXAS)
Trade (NASDAQ:EXAS) Now!

Great Point Partners Snatches Up 2.5 Million Foamix Shares

Jeffrey Jay and David Kroin‘s Great Point Partners filed a Form 13G yesterday in which it reported a significant increase to its stake in Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX). The fund’s position now consists of 2.77 million common shares of the company, which amass 7.57% of its outstanding stock. The fund held just 274,756 Foamix shares on June 30, as per its latest 13F filing. Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) is a clinical-stage pharmaceutical company that mainly works on producing minocycline foam for various skin problems. Recently, the company disclosed positive results from a phase 2 trial evaluating FMX-103 Topical Minocycline Foam for papulopustular rosacea. Over the past 12 months, the company’s stock has gained 34.5%. 17 hedge funds in our database were long Foamix Pharmaceuticals (NASDAQ:FOMX) at the end of June, up by five from the end of March.

Follow Foamix Pharmaceuticals Ltd.
Trade () Now!

We’ll check out two other filings on the next page, including a big move made by Stephen Mandel’s Lone Pine Capital.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!